Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989 was enacted by the Parliament of Australia to regulate the importation, supply, and manufacture of therapeutic goods within the country. This Act was introduced to address the need for a comprehensive regulatory framework that ensures the safety, quality, and efficacy of therapeutic goods, including medicines, medical devices, and blood products. The Act empowers the Therapeutic Goods Administration (TGA), an agency within the Department of Health, to manage the regulation of these goods effectively. The policy objective of the Act is to protect public health by ensuring that therapeutic goods available in Australia meet necessary standards, thereby facilitating access to high-quality health products. This legislative measure underscores the importance of stringent oversight in the therapeutic goods market to safeguard consumer health and wellbeing.

Scope and Application

The Therapeutic Goods Act 1989 applies to a wide range of persons and entities engaged in the manufacture, supply, and advertising of therapeutic goods in Australia. The Act specifically regulates the manufacturing of therapeutic goods, which includes medicines, medical devices, blood, and tissues. The scope of the Act covers all entities involved in the manufacture, packaging, labelling, testing, and importation of these goods. The Act applies nationally, extending its jurisdiction across all states and territories within Australia, ensuring a uniform regulatory framework for therapeutic goods. However, the Act excludes certain products such as food, cosmetics, and most devices not classified as therapeutic goods. Additionally, certain therapeutic goods, such as those used for personal or domestic purposes, may also be exempt from the requirements of the Act. The application of the Act is further refined through subordinate instruments, which can extend or restrict its application based on specific criteria and conditions. These instruments provide detailed guidance on various aspects of the Act, such as licensing, quality standards, and compliance measures, ensuring that the Act's provisions are effectively implemented and enforced.

Key Provisions

The Therapeutic Goods Act 1989, as referenced in the Gazette C2017G00048, includes provisions for the publication of a list of manufacturers granted a licence for the manufacture of therapeutic goods. Section 38 of the Act mandates that the Secretary of the Department of Health, Therapeutic Goods Administration, must publish a notice in writing detailing the grant of a licence to manufacture therapeutic goods. In this instance, the Therapeutic Goods Administration has granted licences to several entities, including The Australian Red Cross Blood Service, Sphere Healthcare Pty Ltd, Wild Child Laboratories Pty Ltd, ATR Packing Services Pty Ltd, and WA Hospitals Central Pharmaceutical Manufacturing Facility T/A AUSPMAN. Each licence is specific to the location and scope of manufacturing activities, as evidenced by the various licence numbers and addresses listed. These entities, once granted a licence, are required to adhere to stringent quality and safety standards as stipulated by the Therapeutic Goods Act 1989. This includes maintaining appropriate facilities and processes to ensure the therapeutic goods produced meet all regulatory requirements. They must also keep detailed records of their manufacturing activities and be subject to inspections by the Therapeutic Goods Administration to verify compliance. Failure to comply with these obligations can result in the suspension or revocation of the licence, which would significantly impact their ability to manufacture and distribute therapeutic goods legally within Australia. Breaches of the Therapeutic Goods Act 1989 can lead to both civil and criminal consequences. For civil offences, the Act allows for the imposition of fines up to a significant amount, depending on the severity of the offence. Criminal offences, such as knowingly manufacturing or supplying therapeutic goods that do not comply with standards, can result in even more severe penalties. For example, individuals and entities can face substantial fines, and in serious cases, imprisonment for up to five years. The Act provides a clear framework for enforcement, ensuring that any non-compliance is met with appropriate and proportionate penalties to maintain public health and safety.